User talk:Noegreen243

Welcome!
Hello, Noegreen243, and welcome to Wikipedia! Thank you for your contributions. I hope you like the place and decide to stay. Unfortunately, your edit to Fight the New Drug does not conform to Wikipedia's Neutral Point of View policy (NPOV). Wikipedia articles should refer only to facts and interpretations that have been stated in print or on reputable websites or other forms of media.

There's a page about the NPOV policy that has tips on how to effectively write about disparate points of view without compromising the NPOV status of the article as a whole. If you are stuck, and looking for help, please come to the Questions page, where experienced Wikipedians can answer any queries you have! Or, to ask for help on your talk page, and a volunteer should respond shortly. Below are a few other good links for newcomers:
 * The five pillars of Wikipedia
 * Contributing to Wikipedia
 * How to edit a page
 * Help pages
 * Tutorial
 * How to write a great article
 * Simplified Manual of Style
 * Task Center – need some ideas of what kind of things need doing? Go here.

I hope you enjoy editing here and being a Wikipedian! Please sign your name on talk pages using four tildes ( ~ ); this will automatically produce your name and the date. If you have any questions, check out Questions or ask me on my talk page. Again, welcome! tgeorgescu (talk) 18:05, 1 November 2021 (UTC)

January 2022
Welcome to Wikipedia. Unfortunately, content you added to Fight the New Drug appears to be a minority or fringe viewpoint, and appears to have given undue weight to this minority viewpoint, and has been reverted. To maintain a neutral point of view, an idea that is not broadly supported by scholarship in its field must not be given undue weight in an article about a mainstream idea. Feel free to use the article's talk page to discuss this, and take a look at the welcome page to learn more about contributing to this encyclopedia. Thank you. tgeorgescu (talk) 22:28, 29 January 2022 (UTC)

March 2022
Hello Noegreen243. The nature of your edits gives the impression you have an undisclosed financial stake in promoting a topic, but you have not complied with Wikipedia's mandatory paid editing disclosure requirements. Paid advocacy is a category of conflict of interest (COI) editing that involves being compensated by a person, group, company or organization to use Wikipedia to promote their interests. Undisclosed paid advocacy is prohibited by our policies on neutral point of view and what Wikipedia is not, and is an especially serious type of COI; the Wikimedia Foundation regards it as a "black hat" practice akin to black-hat search-engine optimization.

Paid advocates are very strongly discouraged from direct article editing, and should instead propose changes on the talk page of the article in question if an article exists. If the article does not exist, paid advocates are extremely strongly discouraged from attempting to write an article at all. At best, any proposed article creation should be submitted through the articles for creation process, rather than directly.

Regardless, if you are receiving or expect to receive compensation for your edits, broadly construed, you are  required by the Wikimedia Terms of Use to disclose your employer, client and affiliation. You can post such a mandatory disclosure to your user page at User:Noegreen243. The template Paid can be used for this purpose – e.g. in the form:. If I am mistaken – you are not being directly or indirectly compensated for your edits – please state that in response to this message. Otherwise, please provide the required disclosure. In either case, do not edit further until you answer this message. Symmachus Auxiliarus (talk) 10:14, 29 March 2022 (UTC)


 * Hi symmachus, I am not a paid advocate. I'm a student who is interested in addressing misconceptions around religion, integral and healthy living, etc. Please explain why "the nature of your edits gives the impression you have an undisclosed financial stake in promoting a topic." Noegreen243 (talk) 21:50, 29 March 2022 (UTC)